In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Edwards' Winning Heart Valve Strategy

Executive Summary

Edwards Lifesciences' strategy of divesting slow-growing businesses and focusing on the relatively underserved niche of late-stage (or what the company now calls advancing stage) cardiovascular disease appears to be paying off. Now the leader in the heart valve market, the company believes that the pressures cardiac surgeons are feeling, coupled with the introduction of devices like drug-eluting stents, might open up new opportunities as surgeons turn to other ways to add value to the treatment of patients with cardiovascular disease.

Related Content


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts